Founded in 2016 and led by CEO Dr. Frank Jiang, CStone focuses on innovative drugs and combination therapies in immuno-oncology. The company has built a portfolio of more than ten assets, including four in various clinical stages. Its lead program, CS1001, a human anti-PD-L1 monoclonal antibody, is completing a Phase I dose-escalation study and is expected to enter registrational trials soon. CStone plans to use new funding to advance clinical development of CS1001 and other clinical-stage assets. The company also intends to expand its pipeline through internal R&D and external partnerships and to recruit additional talent. CStone Pharmaceuticals is a research-based biopharmaceutical company based in Shanghai and Suzhou that develops new treatments across five therapeutic areas: oncology, cardiovascular disease, rheumatoid arthritis, hematology and autoimmune diseases. Led by new CEO Frank Jiang, MD, PhD, the company is advancing multiple discovery programs. It closed a Series A financing to provide capital for development. The company will use the funds to accelerate multiple programs into the clinical stage and to seek new innovations from around the world. The Series A totaled $150 million (about 975 million RMB), bolstering its resources for clinical advancement. No operating metrics or revenues were disclosed in the article.

Total raised

$406M

Funding rounds

2

Latest round

Series B

Latest activity

May 2018